Roche Holding — Chugai
Tracked across 3 events · 36 articles · First seen May 18, 2026 · Last active Sep 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Roche announced on 10 September 2026 that the United States — Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application for Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein…
Impact: Chugai developed Enspryng and is a Roche Group member, so a successful MOGAD approval would support its antibody franchise and royalty economics.
Sep 09, 2026 · 6 articles
International
Impact: Roche Holding — Chugai's stock tumbled, contributing to the list of major losers.
May 18, 2026 · 23 articles
Tech
Impact: Roche Holding — Chugai is a major innovator in the Japanese therapeutic antibody market and Roche is its majority shareholder. This event does not directly impact Roche Holding — Chugai.
Jun 29, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Roche Holding — Chugai live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard